US OptionsDetailed Quotes

RPHM240816P2500

Watchlist

1.15
0.000.00%

15min DelayTrading Mar 22 14:19 ET

0.00High0.00Low

Reneo Pharmaceuticals Stock Discussion

Meltyy

Jun 14 01:35

🚨 M&A Update! 🚨

Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US)$ to acquire EyeBio
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Novartis AG(NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔

Meltyy

May 24 01:44

🚨 May 2024 M&A Update! 🚨

Keep an eye on these M&As: 👀
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Harmony Biosciences(HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔

103849655

May 14 03:52

$Reneo Pharmaceuticals(RPHM.US)$

Stock_Drift

May 13 08:09

5/13/24 watchlist. 🚨🚨🚨🚨

$AC Immune(ACIU.US)$ $Tevogen Bio Holdings(TVGN.US)$ $AMC Entertainment(AMC.US)$ $CareCloud(CCLD.US)$ $Reneo Pharmaceuticals(RPHM.US)$

Jaguar8

May 13 06:36

$Reneo Pharmaceuticals(RPHM.US)$
NEWS
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure announced a merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focusing on advancing OnKure's precision medicines in oncology. The combined company is expected to have $120 million in cash resources at close, funding through 2026. OnKure's lead program, OKI-219, is in a Phase 1 clinical trial for solid tumors.